Paper Details

  1. Home
  2. Paper Details

Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate-to-severe plaque psoriasis: 52-week results from the CLEAR study.

Author: AbramovitsW, BlauveltA, DavenportE, GilloteauI, GuanaA, MehlisS, ReichK, SofenH, TyringS, VanaclochaF, WilliamsN, ZhaoY

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.

Overview

Psoriasis can negatively affect a person's life, impacting clothing choices and sexual function. Secukinumab, a medication that targets a specific immune protein, has shown good results in treating moderate-to-severe psoriasis and psoriatic arthritis, with rapid improvement and lasting effects.
Paper Details　
Original Abstract of the Article :
Psoriasis can greatly impact patients' lives by influencing clothing worn as well as by impairing sexual functioning. Secukinumab, a human monoclonal antibody selectively neutralizing interleukin-17A, has demonstrated good efficacy and safety in the treatment of moderate-to-severe psoriasis and psor...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6084293/

データ提供：米国国立医学図書館（NLM）

Secukinumab: A Potential Oasis in the Desert of Psoriasis

Psoriasis, a chronic skin condition, can significantly impact a person's quality of life, affecting everything from clothing choices to intimate relationships. This study investigated the long-term effects of secukinumab, a monoclonal antibody that targets interleukin-17A, on patients with moderate-to-severe plaque psoriasis. Like a well-equipped camel navigating the challenges of the desert, researchers carefully examined the efficacy and safety of secukinumab in a 52-week study. Their findings revealed that secukinumab demonstrated greater sustained improvements in daily activities and personal relationships compared to another psoriasis treatment, ustekinumab.

Secukinumab: A Beacon of Hope for Psoriasis Patients

The study highlights the potential of secukinumab in significantly improving the lives of patients with psoriasis. The sustained improvements in daily activities and personal relationships suggest that secukinumab may offer a more holistic approach to managing the disease, addressing not just the physical symptoms but also the emotional and social well-being of patients.

Living Well with Psoriasis: A Journey of Hope

The findings of this study offer hope for patients with psoriasis, suggesting that effective treatments can help them navigate the challenges of the disease and lead more fulfilling lives. It is a reminder that even in the face of adversity, there are resources and strategies that can help us overcome obstacles and thrive.

Dr.Camel's Conclusion

The desert of psoriasis can be a challenging landscape to navigate, but this study offers a glimmer of hope. Secukinumab, like a refreshing oasis, provides a potential solution for patients seeking sustained relief from the debilitating effects of the disease. This study reminds us that the search for effective treatments for chronic conditions continues, and there is always reason to be optimistic about the future.

Date :
  1. Date Completed 2018-06-19
  2. Date Revised 2019-12-10
Further Info :

Pubmed ID

28602039

DOI: Digital Object Identifier

PMC6084293

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.